Naloxone Hydrochloride Supply (Medical Pharmaceutical)

The contract entails the manufacture and supply of Naloxone Hydrochloride, identified by NSN 6505-01-699-8878, a commercially available emergency opioid antagonist designed for rapid reversal of opioid overdose. The product must be produced in full compliance with FDA regulations and packaged under strict lot control to ensure traceability, sterility, and regulatory integrity. All units are destined for delivery to locations managed by the Defense Logistics Agency, supporting military and federal medical readiness programs. The item is classified under NAICS code 325412, indicating it falls within pharmaceutical and medicine manufacturing, and the contract is structured as a subcontract under the Department of Defense. The agreement is posted under the DLA’s procurement system with a solicitation date of July 16, 2026, and is assigned the contract number SPE2DP26P1020. While no specific set-aside provisions or small business designations are indicated, the procurement emphasizes adherence to federal medical supply standards and requires full compliance with defense logistics and quality assurance protocols. Deliveries must align with DLA’s distribution requirements, ensuring timely and secure transport to authorized military installations and medical facilities across the continental United States and overseas operations. The contract underscores a critical supply chain function for emergency medical countermeasures within the defense healthcare system.